Jim Lagopoulos
Honorary Professor at ANU School of Medicine and Psychology; CEO and Executive Director of Brain & Mind Hub and Thompson Brain and Mind Healthcare
Data updated
Research Footprint
Jim Lagopoulos appears in 5 tracked papers (2021–2026), most studied alongside Ketamine, across Depressive Disorders, Suicidality and Anxiety Disorders.
Most-cited paper: Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study (57 citations).
Frequent co-authors: Monique Jones.
Background & Research
Jim Lagopoulos is an Australian neuroscientist and psychiatrist-research leader whose work has focused on brain imaging, stress, mood disorders, trauma, and novel treatments for mental illness. He has held senior academic roles in Australian institutions and currently serves as CEO and Executive Director of Brain & Mind Hub and Thompson Brain and Mind Healthcare, while also holding an honorary professorship at ANU. His recent research has been especially visible in oral ketamine trials for chronic suicidality and related neurobiological outcomes.
Key Impact
He is a leading Australian neuroscience and psychiatry researcher known for neuroimaging and for pioneering oral ketamine studies in chronic suicidality, PTSD, and depression.
Collaboration Network
1 collaborator· click a node to visit their profile
Full network →